alexa Light Chain Multiple Myeloma: A Single Institution Series


Journal of Leukemia

Author(s): Rafael RosTamayo, Mara Jos Snchez, Jos Lus Garca de Veas, Teresa Rodrguez, Jos Manuel Puerta

Abstract Share this page

Background: Light chain multiple myeloma represents approximately 15% of myelomas and is considered a poor prognosis subtype. There are few series showing outcomes in real-life patients. Methods: All consecutive symptomatic myeloma cases in our population-based registry from January 1993 to April 2015 have been included in this study. Clinical and laboratory characteristics have been compared in the light chain subtype with respect to other subtypes of myeloma. Overall survival has been analyzed in both groups. Results: 63 patients (15.9%) had light chain myeloma in a series of 395 cases. Median overall survival was 21.1 months (8.9-33.3) in the light chain group versus 37.2 m (30.4-44.1) in other myeloma subtypes (p=0.014). Conclusions: Light chain multiple myeloma should be considered a subtype with poor prognosis, which is associated with several established negative prognostic factors such as stage ISS III, renal failure, male sex, high serum lactate dehydrogenase levels and high serum free light chain ratio.

  • To read the full article Visit
  • Open Access
This article was published in JLU and referenced in Journal of Leukemia

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version